PDCD1 and neoplasm: Notably, in SCLC, PD-L1 expression occurs predominantly in immune cells rather than in tumor cells [35], so down-regulation of the PD-1/PD-L1 pathway may induce host immune responses and contribute to the effect of the antitumor activity of chemotherapy observed in our study.